test

Phase Ib/II study of LGX818 and cetuximab or LGX818, BYL719 and cetuximab in BRAF mutant mCRC

Conditions

Colon | Rectum

What is the purpose of this trial?

Phase Ib: To estimate the MTD and/or RP2D of LGX818 in combination with cetuximab ± BYL719
Phase II: To compare the efficacy of the dual (LGX818, cetuximab) and triple (LGX818, BYL719, cetuximab) combinations.


Participation Guidelines

Age:
18 Years and older
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
Novartis Pharmaceuticals
Dates:
08/01/2014
Last Updated:
Study HIC#:
1404013690